Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients

  • Manabu Yamamoto
  • Hideo Baba
  • Yasushi Toh
  • Takeshi Okamura
  • Yoshihiko Maehara
Original Paper



We recently found an elevation in the pre-operative peritoneal lavage carcinoembryonic antigen (CEA) level to be associated with an earlier detection of recurrent peritoneal dissemination and a poor prognosis.


Two hundred and twenty-nine patients with gastric cancer were intraoperatively measured for tumor markers, CEA and CA125 based on peritoneal lavage using a chemiluminescent enzyme immunoassay.


The patients were divided into four groups. (A) The peritoneal lavage CEA (−) CA125 (−) group (CEA < 0.4 ng/ml, CA125 < 200 ng/ml, n = 129); (B) the peritoneal lavage CEA (−) CA125 (+) group (CEA < 0.4 ng/ml, CA125 ≧ 200 ng/ml, n = 50); (C) the peritoneal lavage CEA (+) CA125 (−) group (CEA ≧ 0.4 ng/ml, CA125 < 200 ng/ml, n = 18); and (D) the peritoneal lavage CEA (+) CA125 (+) group (CEA ≧ 0.4 ng/ml, CA125 ≧ 200 ng/ml, n = 32). The 5-year survival of the patients in groups C and D was 40 and 26%, respectively, which was lower than that of the patients in any other group (group A, B; p < 0.0001). Recurrent sites were both peritoneal dissemination and lymph node/liver in group C, while those were only peritoneal dissemination in group D.


This combined analysis of these markers is therefore considered to be helpful method to accurately estimate the recurrent sites and prognosis for advanced gastric cancer patients.


Tumor marker Recurrence Gastric cancer Peritoneal dissemination 



Carcinoembryonic antigen


Peritoneal lavage cytological positive


  1. Asao T, Fukuda T, Yazawa S, Nagamachi Y (1991) Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 68:44–47PubMedCrossRefGoogle Scholar
  2. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T (2003) Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 6:45–49PubMedCrossRefGoogle Scholar
  3. Bast RC, Freeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337PubMedCrossRefGoogle Scholar
  4. Creasman WT, Rutledge F (1971) The prognostic value of peritoneal cytology in gynecological malignant disease. Am J Obestet Gynecol 110:773–781Google Scholar
  5. Fujimoto T, Zhang B, Minami S, Wang X, Takahashi Y, Mai M (2002) Evaluation of intraoperative intraperitoneal cytology for advanced gastric cancer. Oncology 62:201–208PubMedCrossRefGoogle Scholar
  6. Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res 39:3861–3865PubMedGoogle Scholar
  7. Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M (1986) Clinical significance of serum CA125 value in patients with cancers of the digestive system. Am J Med Sci 292:30–34PubMedCrossRefGoogle Scholar
  8. Kiyasu Y, Kaneshima S, Koga S (1981) Morphogenesis of peritoneal metastasis in human gastric cancer. Cancer Res 41:1236–1239PubMedGoogle Scholar
  9. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimuzu H, Tomita M (1990) Serum carcinoembryonic antigen level increase correlate with tumour progression in patients with differentiated gastric carcinoma following non-curative resection. Cancer Res 50:3952–3955PubMedGoogle Scholar
  10. Maehara Y, Moriguchi S, Yoshida M, Takahashi I, Korenaga D, Sugimachi K (1991a) Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Cancer 67:3006–3009CrossRefGoogle Scholar
  11. Maehara Y, Moriguchi S, Kakeji Y, Orita H, Haraguchi M, Korenaga D, Sugimachi K (1991b) Prognostic factors in adeoncarcinoma in the upper third of the stomach. Surg Gynecl Obstet 173:223–226Google Scholar
  12. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K (2000) Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87:353–357PubMedCrossRefGoogle Scholar
  13. Moore GE, Sako K, Kondo T, Badillo J, Burke E (1961) Assessment of the exfoliation of tumour cells into the body cavities. Surg Gynecol Obestet 112:469–474Google Scholar
  14. Nakata B, Hirakawa K, Kato Y, Yamashita Y, Maeda K, Onoda N, Sawada T, Sowa M (1998) Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83:2488–2492PubMedCrossRefGoogle Scholar
  15. Nishiyama M, Takashima I, Tanaka T, Yoshida K, Toge T, Nagata N, Iwamori S, Tamura Y (1995) Carcinoembryonic antigen levels in the peritoneal cavity: useful gide to peritoneal recurrence and prognosis for gastric cancer. World J Surg 19:133–137PubMedCrossRefGoogle Scholar
  16. Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner M, Nekarda H, Siewert JR (2002) Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 20:1049–1055PubMedCrossRefGoogle Scholar
  17. Schabel FM (1987) Concepts for systemic treatment of micrometastasis. Oncoloy 44:240–244CrossRefGoogle Scholar
  18. Sobin LH, Wittekind CH (1997) Internatinal Union Against Cancer: TNM classification of malignant tumors, 5th edn. Wiley-Liss, New YorkGoogle Scholar
  19. Sugarbeker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope of cure. Oncology 58:96–107CrossRefGoogle Scholar
  20. Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Maehara Y (2004) Prognostic significance of tumour markers in peritoneal lavage in advanced gastric cancer. Oncology 67:19–26PubMedCrossRefGoogle Scholar
  21. Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, Maehara Y (2006) The features of peritoneal dissemination with early gastric cancer. Surg Today 36(9):835–838PubMedCrossRefGoogle Scholar
  22. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugerbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Manabu Yamamoto
    • 1
  • Hideo Baba
    • 2
  • Yasushi Toh
    • 3
  • Takeshi Okamura
    • 3
  • Yoshihiko Maehara
    • 2
  1. 1.Department of SurgeryHiroshima Red Cross Hospital and Atomic Bomb Survivors HospitalHiroshimaJapan
  2. 2.Department of Surgery and Sciences, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of Gastroenterological SurgeryNational Kyushu Cancer CenterFukuokaJapan

Personalised recommendations